Welcome to our dedicated page for Allovir news (Ticker: ALVR), a resource for investors and traders seeking the latest updates and insights on Allovir stock.
AlloVir, Inc. (ALVR) is a clinical-stage biotechnology company pioneering off-the-shelf T-cell therapies for life-threatening viral diseases. This page provides investors and healthcare professionals with timely updates on the company’s scientific advancements, regulatory milestones, and strategic initiatives.
Access the latest press releases, clinical trial data, and partnership announcements in one centralized location. Track developments across AlloVir’s pipeline, including updates on multi-virus targeting therapies, FDA communications, and research collaborations. Our curated news collection ensures you stay informed about innovations in cell therapy and their potential impact on patient care.
Discover updates categorized for clarity: clinical progress, intellectual property filings, executive leadership changes, and industry conference participation. This resource is designed to help stakeholders monitor AlloVir’s progress in developing scalable treatments for immunocompromised patients worldwide.
Bookmark this page for real-time insights into AlloVir’s contributions to viral immunotherapy. Verify facts directly from primary sources and revisit regularly for comprehensive coverage of ALVR’s evolving role in biotechnology.
AlloVir (ALVR) stockholders have approved all proposals, including the merger with Kalaris Therapeutics, a clinical-stage biopharmaceutical company focused on retinal disease treatments. The announcement came during a Special Meeting of Stockholders on March 12, 2025.
Following the merger completion, which is subject to customary closing conditions, the combined entity will operate under the name Kalaris Therapeutics and will trade on the Nasdaq Capital Market under the ticker symbol 'KLRS'.
AlloVir has announced a merger with Kalaris Therapeutics in an all-stock transaction. The combined company will focus on developing TH103, a novel anti-VEGF therapy for retinal diseases, invented by Dr. Napoleone Ferrara. After the merger, pre-Merger AlloVir stockholders will own 25.05% and Kalaris stockholders 74.95% of the combined company. The merged entity will have approximately $100 million in cash, providing runway into Q4 2026, and will trade as Kalaris Therapeutics (KLRS) on Nasdaq. TH103 is currently in Phase 1 trials for neovascular age-related macular degeneration, with initial data expected in Q3 2025. The therapy targets the $14 billion global branded anti-VEGF retinal market.
FAQ
What is the current stock price of Allovir (ALVR)?
What is the market cap of Allovir (ALVR)?
